The ownership structure of Celadon Pharmaceuticals PLC (GB:CEL) stock is a mix of institutional, retail and individual investors. Approximately 0.00% of the company’s stock is owned by Institutional Investors, 3.80% is owned by Insiders and 96.20% is owned by Public Companies and Individual Investors.
The ownership structure of Celadon Pharmaceuticals PLC (GB:CEL) stock is a mix of institutional, retail and individual investors. Approximately 0.00% of the company’s stock is owned by Institutional Investors, 3.80% is owned by Insiders and 96.20% is owned by Public Companies and Individual Investors.
According to the latest TipRanks data, approximately 0.00% of the company's stock is held by institutional investors, 3.80% is held by insiders, and 96.20% is held by retail investors.
What percentage of Celadon Pharmaceuticals PLC (GB:CEL) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.00% of Celadon Pharmaceuticals PLC (GB:CEL) stock is held by institutional investors.
What percentage of Celadon Pharmaceuticals PLC (GB:CEL) stock is held by retail investors?
According to the latest TipRanks data, approximately 96.20% of Celadon Pharmaceuticals PLC (GB:CEL) stock is held by retail investors.
Who owns the most shares of Celadon Pharmaceuticals PLC (GB:CEL)?
Vinodka Murria owns the most shares of Celadon Pharmaceuticals PLC (GB:CEL).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.